Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 5/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993887 | 0.85 | ICMT (0.49) | ICMTCNR1PTGDR2 | |
| SCHEMBL1989207 | 0.81 | L3MBTL1 (0.50) | ICMTCNR1KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL1993789 | 0.73 | L3MBTL1 (0.46) | PTGDR2L3MBTL1TSHRSMN1; SMN2 | |
| SCHEMBL1998282 | 0.68 | L3MBTL1 (0.65) | PTGDR2L3MBTL1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL1990227 | 0.68 | L3MBTL1 (0.50) | ICMTCNR1KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL1991648 | 0.67 | L3MBTL1 (0.62) | CNR1KDM4EL3MBTL1TSHRSMN1; SMN2 | |
| SCHEMBL1998303 | 0.65 | RECQL (0.53) | HTR2CALDH1A1SMN1; SMN2 | |
| SCHEMBL1991929 | 0.65 | ICMT (0.57) | ICMTCNR1 | |
| SCHEMBL900406 | 0.64 | HRH1 (0.58) | KDM4EHTR2CALDH1A1SMN1; SMN2 | |
| SCHEMBL2607204 | 0.64 | NCF1 (0.41) | L3MBTL1JAK1JAK2TYK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | ICMT 1684/4885CNR1 215/4885KDM4E 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.